Page 157 - Read Online

Sharma et al. Microbiome Res Rep 2024;3:3 https://dx.doi.org/10.20517/mrr.2023.51 Page 17 of 17

Microbiota Food Health 2016;35:77-87. DOI PubMed PMC
73. Liu J, Huang XE. Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation.
Asian Pac J Cancer Prev 2014;15:10241-4. DOI PubMed
74. Yang J, Wu Z, Chen Y, et al. Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted
radiosensitization in a murine model for lung cancer. J Cancer Res Clin Oncol 2021;147:411-22. DOI
75. Arunachalam KD. Role of Bifidobacteria in nutrition, medicine and technology. Nutrition Research 1999;19:1559-97. DOI
76. Cronin M, Morrissey D, Rajendran S, et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors.
Mol Ther 2010;18:1397-407. DOI PubMed PMC
77. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy:
selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000;7:269-74. DOI PubMed
78. Michl P, Gress TM. Bacteria and bacterial toxins as therapeutic agents for solid tumors. Curr Cancer Drug Targets 2004;4:689-702.
DOI PubMed
79. Tang Y, Chen C, Jiang B, et al. Bifidobacterium bifidum-mediated specific delivery of nanoparticles for tumor therapy. Int J
Nanomedicine 2021;16:4643-59. DOI PubMed PMC
80. Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to Lactobacillus acidophilus and
Bifidobacterium spp. Immunol Cell Biol 2000;78:80-8. DOI PubMed
81. Ryan RM, Green J, Lewis CE. Use of bacteria in anti-cancer therapies. Bioessays 2006;28:84-94. DOI PubMed
82. Wu C, Wang X, Shang H, Wei H. Construction of a humanized PBMC-PDX model to study the efficacy of a bacterial marker in lung
cancer immunotherapy. Dis Markers 2022;2022:1479246. DOI PubMed PMC
83. Chervin C, Gajewski TF. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immunooncol Technol
2020;8:12-20. DOI PubMed PMC
84. Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: a
novel paradigm for blockade of immune checkpoint inhibitors. Cancer Med 2021;10:1141-54. DOI PubMed PMC
85. Longhi G, van Sinderen D, Ventura M, Turroni F. Microbiota and cancer: the emerging beneficial role of bifidobacteria in cancer
immunotherapy. Front Microbiol 2020;11:575072. DOI PubMed PMC
86. Shi Y, Zheng W, Yang K, et al. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING
signaling. J Exp Med 2020;217:e20192282. DOI PubMed PMC
87. Kaźmierczak-Siedlecka K, Roviello G, Catalano M, Polom K. Gut microbiota modulation in the context of immune-related aspects of
Lactobacillus spp. and Bifidobacterium spp. in gastrointestinal cancers. Nutrients 2021;13:2674. DOI PubMed PMC
88. Liwinski T, Casar C, Ruehlemann MC, et al. A disease-specific decline of the relative abundance of Bifidobacterium in patients with
autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1417-28. DOI
89. Hazan S, Stollman N, Bozkurt HS, et al. Lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased
microbiome diversity associated with SARS-CoV-2 infection severity. BMJ Open Gastroenterol 2022;9:e000871. DOI PubMed
PMC
90. Zhang L, Wan Y, Ma L, Xu K, Cheng B. A low abundance of Bifidobacterium but not Lactobacillius in the feces of Chinese children
with wheezing diseases. Medicine 2018;97:e12745. DOI PubMed PMC
91. van Heck JIP, Gacesa R, Stienstra R, et al. The gut microbiome composition is altered in long-standing type 1 diabetes and associates
with glycemic control and disease-related complications. Diabetes Care 2022;45:2084-94. DOI
92. Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 2020;51:102590. DOI
PubMed PMC
93. Sedighi M, Razavi S, Navab-Moghadam F, et al. Comparison of gut microbiota in adult patients with type 2 diabetes and healthy
individuals. Microb Pathog 2017;111:362-9. DOI
94. Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol
2010;61:69-78. DOI
95. Song Q, Zhang X, Liu W, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-
associated hepatocellular carcinoma. J Hepatol 2023; In press. DOI
96. Turroni F, Ribbera A, Foroni E, van Sinderen D, Ventura M. Human gut microbiota and bifidobacteria: from composition to
functionality. Antonie Van Leeuwenhoek 2008;94:35-50. DOI PubMed
97. Lin C, Lin Y, Zhang H, et al. Intestinal 'infant-type' Bifidobacteria mediate immune system development in the first 1000 days of life.
Nutrients 2022;14:1498. DOI PubMed PMC
98. Alfonsetti M, Castelli V, d’Angelo M. Are we what we eat? Impact of diet on the gut-brain axis in Parkinson’s disease. Nutrients
2022;14:380. DOI PubMed PMC
99. Gong H, Gao H, Ren Q, He J. The abundance of bifidobacterium in relation to visceral obesity and serum uric acid. Sci Rep
2022;12:13073. DOI PubMed PMC
100. O’Callaghan A, van Sinderen D. Bifidobacteria and their role as members of the human gut microbiota. Front Microbiol 2016;7:925.
DOI PubMed PMC